In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CytoCore Inc.

www.cytocoreinc.com

Latest From CytoCore Inc.

News Briefs: Medtronic’s CoreValve Approval; J&J Dx Unit Set For Sale; Google’s Glucometer Contact Lens

Medtronic gains FDA approval for its transcather CoreValve system months earlier than predicted. The Carlyle Group makes binding offer for J&J’s Ortho-Clinical Diagnostics business. Google is developing a wireless glucometer embedded within a contact lens. More news briefs.

Medical Device

Ampersand Medical's Financing Twist

If Ampersand Medical Corp. started with an unusual financing strategy, its current efforts to get listed on a major stock exchange are also a bit innovative and circuitous. The fact that it has managed to survive and progress in a tough era for diagnostics, even though it is a late entrant into the crowded field of cervical cancer screening, is a testament to the value of this approach. Its founder, Peter Gombrich, has started several device and diagnostic companies which have acquired each other or licensed from one another, including AccuMed International and InPath. Now, Ampersand wants to buy AccuMed to gain access to short-term revenues, patents, and technologies related to early-stage cancer detection.
Medical Device Strategy

Ampersand Medical Corp.

Coming in late to the highly competitive and crowded market for cervical cancer screening, Ampersand Medical is doing something completely different. To remove the subjectivity from interpretation of test restuls, it is developing InPath, a comprehensive screening system that uses a cocktail of protein-based biomolecular markers to identify cellular abnormalities associated with cancers at different stages.
Medical Device Platform Technologies

Cancer Diagnostics

New hunters of diagnostic biomarkers hope to improve cancer diagnosis. They envision biomarkers that will allow more accurate disease-stage monitoring, more effective choice of therapy and, ultimately, the development of therapies themselves. Despite the plethora of new technologies, tools, and genomic data, however, cancer-specific markers have provent obe difficult beasts to catch.
Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ampersand Medical Corp.
  • Molecular Diagnostics Inc.
  • CytoCorp Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • CytoCore Inc.
  • Senior Management
  • Robert McCullough, Jr., CEO & CFO
    Richard Domanik, PhD, Pres. & COO
    Eric Cohill, SVP, Sales & Mktg.
  • Contact Info
  • CytoCore Inc.
    Phone: (312) 222-9550
    414 N. Orleans St.
    Ste. 502
    Chicago, IL 60610
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register